IP Library Granted Patent US 8,759,503
Granted Patent B2
US 8,759,503 · App. 13/129,509 · Granted Jun 24, 2014

Truncated CD20 protein, deltaCD20

Inventors: Christophe Ferrand (Dampierre, FR); Marina Deschamps (Besancon, FR); Carole Henry (Besancon, FR); Pierre Tiberghien (Paris, FR); Christophe Borg (Pouilley les Vignes, FR); Pierre-Simon Rohrlich (Besancon, FR)
Assignee: Etablissement Francais du Sang
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,759,503
App. No.
13/129,509
Granted
Jun 24, 2014
Kind
B2
Abstract

Isolated nucleic acid sequence encoding the CD20 gene comprising SEQ ID NO: 5, recombinant vector comprising a nucleic acid sequence placed under the control of one or a plurality of elements required for the expression thereof in a host cell, and method for improving the efficacy of a treatment comprising using a nucleic acid sequence comprising SEQ ID NO: 5.

Claims (8)

1. A An isolated nucleic acid sequence encoding CD20 comprising SEQ ID NO: 5.

2. The isolated nucleic acid sequence according to claim 1 consisting of SEQ ID NO: 5.

3. A recombinant vector comprising a nucleic acid sequence according to claim 1 placed under the control of at least one element required for the expression thereof in a host cell.

4. The recombinant vector according to claim 3 wherein the recombinant vector is selected from the group consisting of plasmids and viral vectors.

5. The recombinant vector according to claim 4 wherein the recombinant vector is a viral vector selected from the group consisting of adenovirus vectors, retrovirus vectors, poxvirus vectors, herpes virus-derived vectors, vectors derived from viruses associated with adenoviruses and alphavirus-derived vectors.

6. The recombinant vector according to claim 4 wherein the recombinant vector is physically associated with at least one compound capable of facilitating the introduction of the recombinant vector into a host cell.

7. The recombinant vector according to claim 6 wherein the at least one compound facilitating the introduction thereof into a host cell is selected from the group consisting of cationic lipids, calcium salts, cationic polymers and polypeptides.

8. The recombinant vector according to claim 3 wherein the at least one element required for expression in a host cell is selected from the group consisting of introns, polyadenylation sites and promoters.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2011
From: FERRAND, CHRISTOPHE; DESCHAMPS, MARINA; HENRY, CAROLE; TIBERGHIEN, PIERRE; BORG, CHRISTOPHE; ROHRLICH, PIERRE-SIMON
To: ETABLISSEMENT FRANCAIS DU SANG
Reel/Frame 026838/0735 →
Priority Claims (1)
FR 08 06444 · Nov 18, 2008 · national
Continuity (1)
Related Publication 20120129167A1 · May 24, 2012